Daniel S. Raccuia, Pharmd Candidate, L. Holle, Pharmd, Bcop, Fhopa
{"title":"FDA approves rolapitant to prevent chemotherapy-induced nausea and vomiting","authors":"Daniel S. Raccuia, Pharmd Candidate, L. Holle, Pharmd, Bcop, Fhopa","doi":"10.1211/pj.2015.20069288","DOIUrl":null,"url":null,"abstract":"Rolapitant is a novel NK1 receptor antagonist that maintains >90% receptor binding up to five days after a single 180-mg dose.","PeriodicalId":12354,"journal":{"name":"Formulary","volume":"71 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2016-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Formulary","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1211/pj.2015.20069288","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Rolapitant is a novel NK1 receptor antagonist that maintains >90% receptor binding up to five days after a single 180-mg dose.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
